Deal Watch: BMS Looks To Molecular Templates’ Engineered Toxin Bodies In Cancer
Executive Summary
Plus recent deals involving AbbVie/Caribou, Sanofi/i2O, Merck & Co./Starpharma, Protalix/SarcoMed, Targovax/Papyrus, Medivir/Ubiquigent, Eton/Azurity
You may also be interested in...
Finance Watch: Eleven Companies Reveal $1.45bn In $100m-Plus VC Deals
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.
Sandoz Strikes $500m Deal For GSK Cephalosporins
Sandoz has struck a deal worth up to $500m for GlaxoSmithKline’s cephalosporin antibiotics business, in a move that the Novartis subsidiary says will reinforce its leadership position in the field.
Ensoma Launches With Takeda Partnership On Myeloablation-Free Gene Therapy
The company also raised a $70m Series A round and is looking to develop “off-the-shelf” gene therapies adapted to settings with fewer resources.